Imperial College London
Portrait Picture

Dr. Elita Jauneikaite

Faculty of Medicine, School of Public Health

Advanced Research Fellow
 
 
 
//

Contact

 

e.jauneikaite

 
 
//

Location

 

Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Bianchi-Jassir:2020:10.1016/j.vaccine.2020.08.052,
author = {Bianchi-Jassir, F and Paul, P and To, K-N and Carreras-Abad, C and Seale, AC and Jauneikaite, E and Madhi, SA and Russell, NJ and Hall, J and Madrid, L and Bassat, Q and Kwatra, G and Le, Doare K and Lawn, JE},
doi = {10.1016/j.vaccine.2020.08.052},
journal = {Vaccine},
pages = {6682--6694},
title = {Systematic review of Group B Streptococcal capsular types, sequence types and surface proteins as potential vaccine candidates.},
url = {http://dx.doi.org/10.1016/j.vaccine.2020.08.052},
volume = {38},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: 21 million pregnant women worldwide (18%) are estimated to carry Group B Streptococcus (GBS), which is a risk for invasive disease in newborns, pregnant women, and stillbirths. Adults ≥ 60 years or with underlying health conditions are also vulnerable to invasive GBS disease. We undertook systematic reviews on GBS organism characteristics including: capsular polysaccharide (serotype), sequence type (multi-locus sequence types (MLST)), and virulence proteins. We synthesised data by at-risk populations, to inform vaccine development. METHODS: We conducted systematic reviews and meta-analyses to estimate proportions of GBS serotypes for at risk populations: maternal colonisation, invasive disease in pregnant women, stillbirths, infants 0-90 days age, and older adults (≥60 years). We considered regional variation and time trends (2001-2018). For these at-risk population groups, we summarised reported MLST and surface proteins. RESULTS: Based on 198 studies (29247isolates), 93-99% of GBS isolates were serotypes Ia, Ib, II, III, IV and V. Regional variation is likely, but data gaps are apparent, even for maternal colonisation which has most data. Serotype III dominates for infant invasive disease (60%) and GBS-associated stillbirths (41%). ST17 accounted for a high proportion of infant invasive disease (41%; 95%CI: 35-47) and was found almost exclusively in serotype III strains, less present in maternal colonisation (9%; 95%CI:6-13),(4%; 95%CI:0-11) infant colonisation, and adult invasive disease (4%, 95%CI:2-6). Percentages of strains with at least one of alp 1, alp2/3, alpha C or Rib surface protein targets were 87% of maternal colonisation, 97% infant colonisation, 93% infant disease and 99% adult invasive disease. At least one of three pilus islands proteins were reported in all strains. DISCUSSION: A hexavalent vaccine (serotypes Ia, Ib, II, III, IV and V) might provide comprehensive cover for all at-risk populations. Survei
AU  - Bianchi-Jassir,F
AU  - Paul,P
AU  - To,K-N
AU  - Carreras-Abad,C
AU  - Seale,AC
AU  - Jauneikaite,E
AU  - Madhi,SA
AU  - Russell,NJ
AU  - Hall,J
AU  - Madrid,L
AU  - Bassat,Q
AU  - Kwatra,G
AU  - Le,Doare K
AU  - Lawn,JE
DO  - 10.1016/j.vaccine.2020.08.052
EP  - 6694
PY  - 2020///
SN  - 0264-410X
SP  - 6682
TI  - Systematic review of Group B Streptococcal capsular types, sequence types and surface proteins as potential vaccine candidates.
T2  - Vaccine
UR  - http://dx.doi.org/10.1016/j.vaccine.2020.08.052
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32888741
UR  - https://www.sciencedirect.com/science/article/pii/S0264410X20310938?via%3Dihub
UR  - http://hdl.handle.net/10044/1/82579
VL  - 38
ER  -
Download